Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals initiated the global Phase 3 Himalayas-1 registrational trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with abiraterone. The company also announced a clinical trial collaboration and supply agreement with Bayer, where Bayer will provide darolutamide for the trial at no cost. The Himalayas-1 trial is expected to enroll approximately 600 patients across 25 countries, with radiographic progression-free survival as the primary endpoint. Oric retains full global development and commercial rights to rinzimetostat.

Oric Pharmaceuticals, Inc. announced that its stockholders approved the Amended and Restated 2020 Equity Incentive Plan at the Annual Meeting on June 18, 2026. Key amendments include reducing the annual 'evergreen' increase from 5% to 4% of outstanding shares while removing a fixed share limit, setting a maximum of 10,000,000 shares for incentive stock options, and eliminating certain administrative flexibilities regarding award modifications. Additionally, stockholders elected two Class III directors, ratified KPMG LLP as the auditor, and approved executive compensation and an annual frequency for future advisory votes on compensation.

ORIC Pharmaceuticals announced it granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees on June 1, 2026. These inducement grants were made pursuant to the company's 2022 Inducement Equity Incentive Plan, subject to the recipients' continued employment. The grants were approved by ORIC's Compensation Committee as a material inducement to employment.

ORIC Pharmaceuticals, a clinical-stage oncology company, announced its management will participate in two investor conferences in June 2026. The company will hold fireside chats and one-on-one meetings at both the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Webcasts of the fireside chats will be available through the investor section of the company’s website.

Oric Pharmaceuticals reported a net loss of $(35.77) million for the first quarter of 2026, an increase from $(30.02) million in the prior year, while net loss per share improved to $(0.34) from $(0.42). The company's cash and cash equivalents rose to $56.40 million, supported by $59.9 million in net proceeds from at-the-market offerings during the quarter. Research and development expenses increased, reflecting continued investment in its lead clinical programs, rinzimetostat and enozertinib, following a strategic pipeline prioritization and workforce reduction in late 2025.

ORIC Pharmaceuticals announced its Q1 2026 financial results and significant operational updates. The company selected rinzimetostat 400 mg once daily as the Recommended Phase 3 Dose for the Himalayas-1 global registrational trial in post-abiraterone mCRPC, expected to start in 1H 2026. Clinical data for rinzimetostat showed a strong safety profile and promising rPFS rates, supporting its potential as a best-in-disease candidate. The company reported a net loss of $(35.8) million for the quarter and maintains a strong cash position of $419.7 million, providing a runway into 2H 2028.

ORIC Pharmaceuticals reported Q1 2026 financial results and provided operational updates, highlighting the selection of rinzimetostat's Recommended Phase 3 Dose (RP3D) for the Himalayas-1 global registrational trial in post-abiraterone mCRPC, expected to begin in 1H 2026. Clinical data for rinzimetostat demonstrated a differentiated safety profile and landmark rPFS rates superior to standard-of-care therapies. The company also reported $419.7 million in cash and investments, providing a runway into 2H 2028, and anticipates several enozertinib clinical updates in 2H 2026.

ORIC Pharmaceuticals, Inc. announced that it granted a total of 216,000 non-qualified stock options and 35,000 restricted stock units to four new non-executive employees on May 1, 2026. These inducement grants were made pursuant to the company's 2022 Inducement Equity Incentive Plan. The grants are subject to specific vesting schedules, with stock options vesting over approximately four years and RSUs over three years, contingent on continued employment.

ORIC Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 18, 2026, at 8:00 a.m. Pacific Time. Stockholders will vote on the election of two Class III directors, the ratification of KPMG LLP as the independent auditor, and the approval of the amended 2020 Equity Incentive Plan. Additionally, advisory votes on executive compensation and its frequency will be held.

ORIC Pharmaceuticals presented multiple posters at the 2026 AACR Annual Meeting, highlighting preclinical data for rinzimetostat (ORIC-944) in prostate cancer. The research indicates that PRC2 activity is a critical therapeutic target observed early and sustained throughout prostate cancer progression and resistance. Rinzimetostat, an allosteric EED inhibitor, demonstrated antitumor activity in combination with darolutamide across various prostate cancer models and showed potential advantages over EZH2 targeting, overcoming acquired resistance mechanisms seen with other inhibitors.